Logo image of ALLR

ALLARITY THERAPEUTICS INC (ALLR) Stock Fundamental Analysis

NASDAQ:ALLR - US0167445008 - Common Stock

1.52 USD
+0.02 (+1.33%)
Last: 8/29/2025, 1:37:14 PM
Fundamental Rating

2

Overall ALLR gets a fundamental rating of 2 out of 10. We evaluated ALLR against 547 industry peers in the Biotechnology industry. The financial health of ALLR is average, but there are quite some concerns on its profitability. ALLR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year ALLR has reported negative net income.
ALLR had a negative operating cash flow in the past year.
ALLR had negative earnings in each of the past 5 years.
ALLR had a negative operating cash flow in each of the past 5 years.
ALLR Yearly Net Income VS EBIT VS OCF VS FCFALLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

ALLR's Return On Assets of -116.28% is on the low side compared to the rest of the industry. ALLR is outperformed by 78.25% of its industry peers.
Looking at the Return On Equity, with a value of -202.65%, ALLR is doing worse than 66.54% of the companies in the same industry.
Industry RankSector Rank
ROA -116.28%
ROE -202.65%
ROIC N/A
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALLR Yearly ROA, ROE, ROICALLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALLR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLR Yearly Profit, Operating, Gross MarginsALLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

5

2. Health

2.1 Basic Checks

ALLR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALLR has more shares outstanding
Compared to 1 year ago, ALLR has an improved debt to assets ratio.
ALLR Yearly Shares OutstandingALLR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M
ALLR Yearly Total Debt VS Total AssetsALLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -8.68, we must say that ALLR is in the distress zone and has some risk of bankruptcy.
ALLR has a worse Altman-Z score (-8.68) than 69.84% of its industry peers.
There is no outstanding debt for ALLR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.68
ROIC/WACCN/A
WACCN/A
ALLR Yearly LT Debt VS Equity VS FCFALLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 2.31 indicates that ALLR has no problem at all paying its short term obligations.
ALLR's Current ratio of 2.31 is on the low side compared to the rest of the industry. ALLR is outperformed by 70.75% of its industry peers.
ALLR has a Quick Ratio of 2.31. This indicates that ALLR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALLR (2.31) is worse than 68.56% of its industry peers.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.31
ALLR Yearly Current Assets VS Current LiabilitesALLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 87.26% over the past year.
EPS 1Y (TTM)87.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.92% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.94%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5Y18.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALLR Yearly Revenue VS EstimatesALLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2M 4M 6M 8M
ALLR Yearly EPS VS EstimatesALLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -500K -1M -1.5M

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALLR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALLR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLR Price Earnings VS Forward Price EarningsALLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLR Per share dataALLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20K -40K -60K -80K -100K

4.3 Compensation for Growth

ALLR's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%

0

5. Dividend

5.1 Amount

No dividends for ALLR!.
Industry RankSector Rank
Dividend Yield N/A

ALLARITY THERAPEUTICS INC

NASDAQ:ALLR (8/29/2025, 1:37:14 PM)

1.52

+0.02 (+1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-15 2025-08-15/amc
Earnings (Next)N/A N/A
Inst Owners0.61%
Inst Owner Change111.22%
Ins OwnersN/A
Ins Owner Change0%
Market Cap22.92M
Analysts82.86
Price Target9.18 (503.95%)
Short Float %3.76%
Short Ratio1.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)80%
PT rev (3m)80%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.88
P/tB 1.88
EV/EBITDA N/A
EPS(TTM)-123690
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -116.28%
ROE -202.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 2.31
Altman-Z -8.68
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
EPS Next Y99.94%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5Y18.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.21%
OCF growth 3YN/A
OCF growth 5YN/A